What are the risk factors for Allergic Bronchopulmonary Aspergillosis (ABPA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Risk Factors for Allergic Bronchopulmonary Aspergillosis (ABPA)

The primary risk factors for ABPA are asthma and cystic fibrosis, with genetic predisposition playing a significant role in determining which patients with these conditions develop ABPA. 1

Major Predisposing Conditions

Respiratory Disorders

  • Asthma: Most common predisposing condition, with ABPA occurring in 7-14% of corticosteroid-dependent asthmatics 1
  • Cystic Fibrosis (CF): Approximately 7-9% of CF patients develop ABPA 2
  • CFTR mutations: Even in patients without classic CF, CFTR gene variants can predispose to ABPA 3, 2
  • Bronchiectasis: Can be both a cause and consequence of ABPA 4
  • COPD: Less common but recognized predisposing condition 1

Genetic Factors

  • HLA associations: Specific HLA-DR2 and HLA-DR5 haplotypes increase susceptibility 5
  • IL-4 receptor alpha chain polymorphisms: Affect Th2 immune responses 2
  • IL-10 promoter polymorphisms: Influence inflammatory regulation 2
  • Surfactant protein A2 (SP-A2) polymorphisms: Affect innate immunity 2

Immunological Factors

  • Atopy: General predisposition to allergic responses 2
  • Th2-skewed immune responses: Heightened responses to Aspergillus antigens 2, 6
  • Impaired mucociliary clearance: Common in both asthma and CF 6

Environmental and Microbiological Factors

  • Airway colonization with Aspergillus fumigatus: Most common causative organism 1
  • Repeated exposure to Aspergillus spores: Environmental exposure is necessary but not sufficient 7
  • Persistent fungal growth in airways: Particularly in patients with mucus plugging 6

Disease Progression Risk Factors

  • Delayed diagnosis: Increases risk of progression to bronchiectasis 4
  • Recurrent exacerbations: Associated with worse outcomes 4
  • Inadequate treatment: Particularly insufficient corticosteroid therapy 1
  • High fungal burden: Associated with more severe disease 1

Clinical Presentation Risk Factors

  • Mucus plugging: Characteristic finding that increases risk of bronchiectasis 1
  • High-attenuation mucus (HAM): Associated with more severe disease 1
  • Central bronchiectasis: Classic radiological finding associated with ABPA 4
  • Elevated total IgE (>500 IU/mL): Key diagnostic marker and risk factor 1
  • Peripheral blood eosinophilia: Common finding in ABPA patients 1

Clinical Implications

  • Patients with asthma or CF should be screened for Aspergillus sensitization, particularly those with difficult-to-control disease 1
  • Early identification and treatment are crucial to prevent progression to bronchiectasis 1, 4
  • Genetic testing may be warranted in patients with ABPA to identify underlying CFTR mutations, especially with atypical presentations 3
  • Regular monitoring of total IgE levels helps assess disease activity and response to therapy 1, 4

Understanding these risk factors is essential for early identification of at-risk patients and timely intervention to prevent the development of permanent lung damage from ABPA.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis.

Clinical & developmental immunology, 2011

Guideline

Aspergillus and Bronchiectasis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Chapter 18: Allergic bronchopulmonary aspergillosis.

Allergy and asthma proceedings, 2012

Research

Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.